Myeloid sarcoma
diseaseOn this page
Also known as chloromaextramedullary myeloid tumorextramedullary myeloid tumourMSsarcoma, myeloid, malignant
Summary
Myeloid sarcoma (MONDO:0006861) is a cancer and 42 clinical trials. Top therapeutic interventions include dexrazoxane, sorafenib, and 2-mercaptoethanesulfonic acid. A subtype of sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
- Clinical trials: 42
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | <1 / 1 000 000 | 0.02 | Europe | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | myeloid sarcoma |
| Mondo ID | MONDO:0006861 |
| EFO | EFO:1001052 |
| MeSH | D023981 |
| Orphanet | 86850 |
| DOID | DOID:8683 |
| ICD-10-CM | C92.3 |
| ICD-11 | 1988933820, 921720320 |
| NCIT | C3520 |
| UMLS | C4721505 |
| MedGen | 1656669 |
| GARD | 0012763 |
| MedDRA | 10028562 |
| Is cancer (heuristic) | yes |
Also known as: chloroma · extramedullary myeloid tumor · extramedullary myeloid tumour · MS · myeloid sarcoma · sarcoma, myeloid, malignant
Data availability: 1 cell line.
Disease family
This is a subtype of sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › myeloid sarcoma
Related subtypes (21): rectum sarcoma, ectomesenchymoma, spindle cell sarcoma, colon sarcoma, sarcomatosis, dendritic cell sarcoma, orbit sarcoma, sarcoma G1, uterine corpus sarcoma, giant cell tumor of soft tissue, lymphangiosarcoma, endometrioid stromal sarcoma, small cell sarcoma, chondrosarcoma, osteosarcoma, reticulum cell sarcoma, Ewing sarcoma, sarcoma of cervix uteri, soft tissue sarcoma, mast cell sarcoma, bone sarcoma
Subtypes (1): granulocytic sarcoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Asparaginase | Phase 3 (in late-stage trials) |
| Bortezomib | Phase 3 (in late-stage trials) |
| Cytarabine | Phase 3 (in late-stage trials) |
| Etoposide | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 42.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 27 |
| PHASE2 | 7 |
| PHASE1 | 3 |
| PHASE1/PHASE2 | 2 |
| EARLY_PHASE1 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01371981 | PHASE3 | COMPLETED | Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
| NCT02790515 | PHASE2 | ACTIVE_NOT_RECRUITING | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation |
| NCT03589729 | PHASE2 | RECRUITING | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers |
| NCT04797767 | PHASE1/PHASE2 | RECRUITING | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms |
| NCT06384976 | PHASE2 | ACTIVE_NOT_RECRUITING | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis |
| NCT06782724 | PHASE2 | RECRUITING | Psilocybin Therapy for Psychological Distress in Palliative Patients |
| NCT07028086 | PHASE2 | RECRUITING | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma |
| NCT00872053 | PHASE1/PHASE2 | COMPLETED | Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis |
| NCT02259348 | PHASE2 | TERMINATED | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation |
| NCT02658487 | PHASE2 | COMPLETED | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia |
| NCT05735184 | PHASE1 | RECRUITING | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML |
| NCT06999434 | PHASE1 | RECRUITING | Exploring the Utility of [18F]3F4AP for Demyelination Imaging |
| NCT05102682 | PHASE1 | COMPLETED | Robotics for Mobility Rehabilitation in MS |
| NCT06775912 | EARLY_PHASE1 | RECRUITING | Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases |
| NCT06548620 | EARLY_PHASE1 | WITHDRAWN | A Study of RD06-04 in Patients With Active Autoimmune Diseases |
| NCT04415372 | Not specified | ENROLLING_BY_INVITATION | Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis |
| NCT05865405 | Not specified | ACTIVE_NOT_RECRUITING | A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis |
| NCT06111612 | Not specified | RECRUITING | Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement |
| NCT06770959 | Not specified | NOT_YET_RECRUITING | Frequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study |
| NCT06849882 | Not specified | RECRUITING | Dubousset Functional Test: an Investigation of Its Validity and Reliability in Individuals with Multiple Sclerosis |
| NCT07087873 | Not specified | RECRUITING | Assessment of Transcranial Alternating Current Stimulation’s Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases |
| NCT07202195 | Not specified | RECRUITING | At Home Use of Stimulation Suits for Managing MS Symptoms |
| NCT07222618 | Not specified | RECRUITING | Selfie Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS |
| NCT07235644 | Not specified | ACTIVE_NOT_RECRUITING | Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis |
| NCT07304960 | Not specified | NOT_YET_RECRUITING | Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder |
| NCT07521384 | Not specified | ENROLLING_BY_INVITATION | Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy |
| NCT01128075 | Not specified | COMPLETED | Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects |
| NCT01628276 | Not specified | COMPLETED | Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study |
| NCT02490943 | Not specified | COMPLETED | A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS |
| NCT03155334 | Not specified | UNKNOWN | Understanding Evaluation of Patient Information Sheets by User Testing Method |
| NCT03316404 | Not specified | COMPLETED | Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response |
| NCT04095377 | Not specified | COMPLETED | Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019. |
| NCT04148313 | Not specified | WITHDRAWN | A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis |
| NCT04379661 | Not specified | COMPLETED | SUNLIGHT Study: Online Support Groups for MS to Address COVID-19 |
| NCT04530955 | Not specified | UNKNOWN | Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) |
| NCT04822623 | Not specified | UNKNOWN | Imaging Evaluation of Central Nervous Autoimmune Diseases |
| NCT05435404 | Not specified | COMPLETED | Qualitative Study Patient & Physician Experiences Botox COVID-19 |
| NCT05857280 | Not specified | UNKNOWN | EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2) |
| NCT05912595 | Not specified | UNKNOWN | EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2) |
| NCT05991297 | Not specified | COMPLETED | Effects of Deep Sensory Assisted Rehabilitation on Gait and Balance in Patients With Multiple Sclerosis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXRAZOXANE | 4 | 3 |
| SORAFENIB | 4 | 3 |
| 2-MERCAPTOETHANESULFONIC ACID | 4 | 2 |
| CLADRIBINE | 4 | 2 |
| ASPARAGINASE | 4 | 1 |
| BLINATUMOMAB | 4 | 1 |
| BORTEZOMIB | 4 | 1 |
| DAUNORUBICIN | 4 | 1 |
| GEMTUZUMAB OZOGAMICIN | 4 | 1 |
| MITOXANTRONE | 4 | 1 |
| QUIZARTINIB | 4 | 1 |
| PSILOCYBIN | 3 | 1 |
| VOSAROXIN | 3 | 1 |
| MEBUFOTENIN | 2 | 1 |
| ZIFTOMENIB | 1 | 1 |
| CHEMBL4776881 | 0 | 2 |